After moving from Sierra Leone to London, guest columnist Richard Bayliss received a proper diagnosis and care plan for his sickle cell.

Richard Bayliss is 44 years old and has sickle cell disease with hemoglobin SS disease. He’s in the final year of a master’s ...

In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was ...

As is the case for institutions treating the disease, a majority of the sickle cell patients at SSM Health Cardinal Glennon Children’s Hospital are African American. The hospital recognized the need ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston Children's Hospital—have been game-changing for the patients who have ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...